The only thing I’ll say is this: the share price will start...

The only thing I’ll say is this: the share price will start moving when we see consistent revenue growth quarter after quarter and regular contract wins.

In his keynote at the Bionics Institute's 2023 Innovation Lecture, Dr. Andreas Fouras, CEO of 4DMedical, highlighted the challenges medtech companies face in securing financial support compared to mining firms. He emphasized that while mining companies often attract substantial investment due to Australia's resource-focused economy, medtech ventures like 4DMedical encounter hurdles stemming from longer R&D timelines, complex regulatory requirements, and a general investor unfamiliarity with the sector. This environment can lead to undervaluation and limited local backing for innovative medical technologies.

Australia has a resource-heavy investment culture. Mining, energy, and materials dominate the ASX and most retail and even many institutional investors are more familiar with those industries. It’s what the country’s economy has been built around, and it’s where investors are generally more comfortable .So when a medtech company like 4DMedical comes along, a lot of Aussie investors either don’t understand it well or don’t have the patience for it. That leads to undervaluation or weak support locally, even if the tech is world-leading.It's not just 4DMedical — it’s common across the sector.Biotech and medtech companies often get more traction overseas (especially in the U.S.).

Aussie success stories like CSL, ResMed, PME and Cochlear often had to build credibility internationally before getting big support at home.In some cases, companies even choose to list or dual-list overseas — typically on U.S. markets. 4DMedical is on that same path — it's just earlier in the journey. The tech is world-class, the problem it solves is global, and like those other companies, it’s proving itself offshore first (US ) with VA, DoD and Phillips.

We’re not far off at all. The market may not fully be pricing that in yet — but once consistent revenue growth kicks in and more contracts land particularly US, things could shift quickly.

its still high-risk, high-reward, but like I always say, I’m a believer, and I’m holding until the end — for better or worse. There are plenty of lifestyle companies in the ASX small caps that basically just sell hope, and honestly, a lot of them are worse than 4DX in every way. That’s why I’m happy holding — the tech works and proven solid, the partnerships with US Phillips and contracts in OZ are strong, and the potential and foundation arethere.

Next we should be expecting more revenue quarter over quarter — I’m not expecting big jumps, but as long as we see steady growth from one quarter to the next, that’s a solid sign of revenue progress.

IMHO DYOR